UA95978C2 - Ингибитор активации stat3/5 - Google Patents
Ингибитор активации stat3/5Info
- Publication number
- UA95978C2 UA95978C2 UAA200904059A UAA200904059A UA95978C2 UA 95978 C2 UA95978 C2 UA 95978C2 UA A200904059 A UAA200904059 A UA A200904059A UA A200904059 A UAA200904059 A UA A200904059A UA 95978 C2 UA95978 C2 UA 95978C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- stat3
- activation inhibitor
- hydrogen atom
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Объектом данного изобретения является ингибитор активации STAT3/5. В данном изобретении заявляется ингибитор активации STAT3/5, который содержит ароматическое соединение, представленное общей формулой, или ее соли как действующий ингредиент: EMBED ISISServer , (1) где Х1 представляет атом азота или группу -СН=, R1 представляет группу -Z-R6, в которой Z представляет группу -СО-, группу -СН(ОН)- или подобные, R6 представляет 15-членную моноциклическую, дициклическую или трехциклическую насыщенную или ненасыщенную гетероциклическую группу, которая имеет 1-4 атома азота, атомы кислорода или атомы серы, R2 представляет атом водорода или атом галогена, Y представляет группу -O-, группу -СО-, группу -СН(ОН)- или низшую алкиленовую группу, и А представляет группу EMBED ISISServer , (2) где R3 представляет атом водорода, низшую алкоксигрупу или подобные, р представляет 1 или 2, R4 представляет имидазолил-низшую алкильную группу или подобные.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006271172 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA95978C2 true UA95978C2 (ru) | 2011-09-26 |
Family
ID=38896700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200904059A UA95978C2 (ru) | 2006-10-02 | 2007-02-10 | Ингибитор активации stat3/5 |
Country Status (20)
Country | Link |
---|---|
US (2) | US8263599B2 (ru) |
EP (2) | EP2089373A1 (ru) |
JP (1) | JP5068821B2 (ru) |
KR (1) | KR101148805B1 (ru) |
CN (1) | CN101522657B (ru) |
AR (1) | AR063073A1 (ru) |
AU (1) | AU2007305511A1 (ru) |
BR (1) | BRPI0717218A2 (ru) |
CA (1) | CA2665000C (ru) |
HK (1) | HK1131619A1 (ru) |
IL (1) | IL197723A (ru) |
MX (1) | MX2009003256A (ru) |
MY (1) | MY150229A (ru) |
NO (1) | NO20090856L (ru) |
NZ (1) | NZ598061A (ru) |
RU (1) | RU2489148C2 (ru) |
TW (1) | TWI336699B (ru) |
UA (1) | UA95978C2 (ru) |
WO (1) | WO2008044667A1 (ru) |
ZA (1) | ZA200901874B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
BRPI0615934A2 (pt) | 2005-09-16 | 2011-05-31 | Arrow Therapeutics Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um derivado de bifenila, composição farmacêutica, e, produto |
ZA200804445B (en) * | 2005-12-05 | 2009-11-25 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
KR101696936B1 (ko) | 2008-07-10 | 2017-01-16 | 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 | 퀴놀린카르복사미드 유도체를 유효 성분으로 하는 stat3 저해제 |
JP5688918B2 (ja) * | 2009-04-28 | 2015-03-25 | 大塚製薬株式会社 | 医薬組成物 |
CN102725287B (zh) | 2009-12-28 | 2015-07-01 | 一般社团法人创药分子谷项目支援机构 | 1,3,4-噁二唑-2-甲酰胺化合物 |
MY160875A (en) * | 2010-01-29 | 2017-03-31 | Otsuka Pharma Co Ltd | Di-substituted pyridine derivatives as anticancers |
BR112013007841B1 (pt) | 2010-10-04 | 2020-03-03 | Otsuka Pharmaceutical Co., Ltd | Derivados de 4- (metilaminofenoxi) piridina - 3 - yl - benzamida para tratamento de câncer |
CN102921007B (zh) * | 2011-08-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
EP2854819B1 (en) * | 2012-05-25 | 2020-01-15 | The Governing Council of the University of Toronto | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and medical use thereof |
CN103880707B (zh) * | 2012-12-19 | 2016-04-13 | 上海交通大学医学院 | Stat3小分子抑制剂及其应用 |
EP3019475A1 (en) * | 2013-07-08 | 2016-05-18 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
AR100530A1 (es) * | 2014-05-19 | 2016-10-12 | Merial Inc | Compuestos antihelmínticos |
RU2707094C2 (ru) * | 2014-05-30 | 2019-11-22 | Зе Гавернинг Каунсл Оф Зе Юниверсити Оф Торонто | Соединения сульфонамида и их применение в качестве ингибиторов stat5 |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
EP3615020B1 (en) | 2017-04-26 | 2024-04-10 | University of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
TWI650120B (zh) * | 2017-07-21 | 2019-02-11 | 寶騰生醫股份有限公司 | 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途 |
US10882821B1 (en) | 2017-09-26 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
CN112203501A (zh) | 2018-06-01 | 2021-01-08 | 日洋服务株式会社 | 植物的栽培方法和植物的栽培装置 |
CN111763217B (zh) * | 2019-03-30 | 2022-06-28 | 上海凌达生物医药有限公司 | 一类噻吩并氮杂环类化合物、制备方法和用途 |
EP3946360A4 (en) | 2019-04-05 | 2023-05-10 | Kymera Therapeutics, Inc. | STAT DEGRADING AGENTS AND THEIR USES |
WO2021024375A1 (ja) | 2019-08-06 | 2021-02-11 | 正月 白川 | 植物の栽培方法及び植物の栽培装置 |
RU2742188C1 (ru) * | 2020-07-22 | 2021-02-03 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. | Способ лечения оптической нейропатии у больных с отечным экзофтальмом |
CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE629102A (ru) | 1961-03-29 | |||
US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
NL7111711A (ru) | 1970-09-17 | 1972-03-21 | ||
GB1494117A (en) | 1974-11-02 | 1977-12-07 | Bayer Ag | Process for the preparation of acid amides |
DE2707659A1 (de) * | 1977-02-23 | 1978-08-24 | Bayer Ag | Selbstvernetzbare polyurethane |
DE2707660C2 (de) * | 1977-02-23 | 1985-12-19 | Bayer Ag, 5090 Leverkusen | Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung |
DE2812252A1 (de) * | 1978-03-21 | 1979-10-04 | Bayer Ag | 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel |
US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
EP0500495A3 (en) * | 1991-02-21 | 1993-04-07 | Ciba-Geigy Ag | Thermosetting composition |
ATE159515T1 (de) * | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
CA2166413A1 (en) | 1993-06-30 | 1995-01-12 | Richard James Arrowsmith | Anti-atherosclerotic diaryl compounds |
AU702423B2 (en) | 1995-06-07 | 1999-02-18 | Institute Of Materia Medica | Chalcone retinoids and methods of use of same |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
EP1060171A2 (de) | 1998-02-06 | 2000-12-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase-inhibitoren |
US6489327B1 (en) | 1998-02-06 | 2002-12-03 | Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. | Tryptase inhibitors |
AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
TWI245035B (en) | 1998-06-26 | 2005-12-11 | Ono Pharmaceutical Co | Amino acid derivatives and a pharmaceutical composition comprising the derivatives |
ES2230864T3 (es) | 1998-07-24 | 2005-05-01 | Teijin Limited | Derivados del acido antranilico. |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
EP1150955A2 (en) | 1999-02-04 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
WO2001002359A1 (fr) | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Composes heterocycliques et leurs applications en medecine |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
JP2001089450A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
EP1256341A4 (en) | 2000-02-15 | 2004-12-08 | Teijin Ltd | ANTI-CANCER MEDICINAL PRODUCT COMPRISING AN ANTHRANILIC ACID DERIVATIVE AS AN ACTIVE INGREDIENT |
BR0111206A (pt) | 2000-05-22 | 2003-04-15 | Aventis Pharma Inc | Derivados de arilmetilamina para uso como inibidores de triptase |
GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
WO2002026191A2 (en) | 2000-09-28 | 2002-04-04 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
WO2002032408A2 (en) | 2000-10-20 | 2002-04-25 | Novartis Ag | Combinations of a thyromimetic compound and a statin |
EP1211235A3 (en) | 2000-11-30 | 2004-01-02 | JFE Chemical Corporation | Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof |
JP2004269356A (ja) | 2000-12-27 | 2004-09-30 | Ajinomoto Co Inc | 創傷部癒着防止剤 |
GB2374009A (en) | 2001-02-12 | 2002-10-09 | Novartis Ag | Method of treating hair loss |
CZ20033455A3 (en) | 2001-06-20 | 2004-06-16 | Pfizer Products Inc. | Novel sulfonic acid derivatives |
JP2005504059A (ja) | 2001-08-24 | 2005-02-10 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 疾患を処置するための置換アリール7−アザ[2.2.1]ビシクロヘプタン |
BR0213452A (pt) | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | Derivados de piperazina com atividade antagonista receptora de ccr1 |
WO2003035602A1 (fr) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
EP1480977A2 (en) | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Substituted aryl compounds for treatment of disease |
FR2836917B1 (fr) * | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
JP2004035475A (ja) | 2002-07-03 | 2004-02-05 | Ajinomoto Co Inc | TGFβ作用抑制剤 |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
ES2346972T3 (es) | 2003-07-24 | 2010-10-22 | Leo Pharma A/S | Compuestos novedosos de aminobenzofenona. |
MX2007001215A (es) * | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
ZA200804445B (en) * | 2005-12-05 | 2009-11-25 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
TWI440638B (zh) * | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2007
- 2007-02-10 UA UAA200904059A patent/UA95978C2/ru unknown
- 2007-10-01 AR ARP070104333A patent/AR063073A1/es unknown
- 2007-10-02 KR KR1020097006358A patent/KR101148805B1/ko not_active IP Right Cessation
- 2007-10-02 MX MX2009003256A patent/MX2009003256A/es active IP Right Grant
- 2007-10-02 US US12/311,500 patent/US8263599B2/en not_active Expired - Fee Related
- 2007-10-02 ZA ZA200901874A patent/ZA200901874B/xx unknown
- 2007-10-02 JP JP2009529959A patent/JP5068821B2/ja not_active Expired - Fee Related
- 2007-10-02 AU AU2007305511A patent/AU2007305511A1/en not_active Abandoned
- 2007-10-02 BR BRPI0717218-4A2A patent/BRPI0717218A2/pt not_active IP Right Cessation
- 2007-10-02 CN CN200780036608.8A patent/CN101522657B/zh not_active Expired - Fee Related
- 2007-10-02 MY MYPI20091324A patent/MY150229A/en unknown
- 2007-10-02 TW TW096136957A patent/TWI336699B/zh not_active IP Right Cessation
- 2007-10-02 WO PCT/JP2007/069645 patent/WO2008044667A1/en active Application Filing
- 2007-10-02 EP EP07829383A patent/EP2089373A1/en not_active Withdrawn
- 2007-10-02 CA CA2665000A patent/CA2665000C/en not_active Expired - Fee Related
- 2007-10-02 EP EP13153028.9A patent/EP2612858A1/en not_active Withdrawn
- 2007-10-02 NZ NZ598061A patent/NZ598061A/xx not_active IP Right Cessation
- 2007-10-02 RU RU2009116653/15A patent/RU2489148C2/ru not_active IP Right Cessation
-
2009
- 2009-02-25 NO NO20090856A patent/NO20090856L/no not_active Application Discontinuation
- 2009-03-19 IL IL197723A patent/IL197723A/en not_active IP Right Cessation
- 2009-12-03 HK HK09111385.1A patent/HK1131619A1/xx not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/526,283 patent/US20120322807A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR101148805B1 (ko) | 2012-07-10 |
HK1131619A1 (en) | 2010-01-29 |
US20100210661A1 (en) | 2010-08-19 |
CA2665000A1 (en) | 2008-04-17 |
JP2010505762A (ja) | 2010-02-25 |
EP2612858A1 (en) | 2013-07-10 |
MX2009003256A (es) | 2009-04-08 |
EP2089373A1 (en) | 2009-08-19 |
CA2665000C (en) | 2015-03-24 |
NZ598061A (en) | 2013-05-31 |
TWI336699B (en) | 2011-02-01 |
WO2008044667A1 (en) | 2008-04-17 |
IL197723A (en) | 2015-02-26 |
TW200823189A (en) | 2008-06-01 |
AR063073A1 (es) | 2008-12-23 |
CN101522657B (zh) | 2014-10-15 |
US8263599B2 (en) | 2012-09-11 |
KR20090043008A (ko) | 2009-05-04 |
AU2007305511A1 (en) | 2008-04-17 |
BRPI0717218A2 (pt) | 2013-09-24 |
CN101522657A (zh) | 2009-09-02 |
IL197723A0 (en) | 2009-12-24 |
NO20090856L (no) | 2009-03-27 |
RU2009116653A (ru) | 2010-11-10 |
US20120322807A1 (en) | 2012-12-20 |
MY150229A (en) | 2013-12-31 |
RU2489148C2 (ru) | 2013-08-10 |
JP5068821B2 (ja) | 2012-11-07 |
ZA200901874B (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA95978C2 (ru) | Ингибитор активации stat3/5 | |
TW200619214A (en) | Aromatic compound | |
MY146514A (en) | Diarylether derivatives as antitumor agents | |
TW200731013A (en) | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
UA88329C2 (en) | Dna-pk inhibitors | |
MX2009009540A (es) | Inhibidores de metaloproteasa que contienen una porcion heterociclica. | |
TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
MY152972A (en) | Azabicyclo compound and salt thereof | |
TW200728914A (en) | A salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
SG140618A1 (en) | Amide compound | |
DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
WO2007105058A3 (en) | Pyrazole compounds | |
MY179032A (en) | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors | |
UA95972C2 (ru) | Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а | |
IN2012DN01325A (ru) | ||
MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение | |
MX2009003073A (es) | Derivado de 2-piridincarboxamida que tiene efecto activador de gk. | |
UA104449C2 (ru) | Комбинация, содержащая метотрексат и ингибитор дгодг | |
TW200732284A (en) | Amine compound and pharmaceutical use thereof | |
EP1741714A4 (en) | HETEROCYLIC COMPOUND AND ANTI-MALIGNANT TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | |
MX2010002662A (es) | Aminoquinolonas espirociclicas como inhibidores de gsk-3. | |
MX2011011764A (es) | Compuestos de carboxamida y su uso como inhibidores de calpaina. |